Batch J, Ma A, Bird D, Noble R, Charles B, Ravenscroft P, Cameron D
Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia.
Eur J Clin Pharmacol. 1990;38(5):465-7. doi: 10.1007/BF02336685.
The effect of altering the timing of gliclazide administration in relation to a meal was studied in ten type 2 (non-insulin dependent) chronically treated diabetics. Gliclazide was given 30 min before, at the start of and 30 min after breakfast or omitted altogether. Plasma gliclazide was present at greater than 2 mg/l throughout the study periods. Administration at 30 min after the meal significantly delayed the time to peak for plasma gliclazide. No significant difference was noted in plasma glucose, insulin or c-peptide patterns with any protocol. It is concluded that, in clinical practice, with chronically treated diabetics the timing of gliclazide ingestion in relation to meals is not critical.